ADC Therapeutics (ADCT) Operating Leases (2019 - 2026)

ADC Therapeutics has disclosed Operating Leases across 8 years of filings, most recently posting $991000.0 for Q1 2026.

• Operating Leases for Q1 2026 came in at $991000.0, down 87.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $991000.0 (down 87.47% YoY), and the FY2025 annual result was $1.0 million, down 87.07% from the prior year.
• Operating Leases came in at $991000.0 for Q1 2026 at ADC Therapeutics, down from $1.0 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $10.2 million in Q4 2023 to a low of $991000.0 in Q1 2026.
• The 5-year median for Operating Leases is $7.9 million (2025), against an average of $6.0 million.
• Across the five-year window, Operating Leases surged 55.09% in 2023 and plunged 87.47% in 2026, its largest moves.
• ADC Therapeutics' Operating Leases stood at $6.6 million in 2022, then soared by 55.09% to $10.2 million in 2023, then slipped by 21.46% to $8.0 million in 2024, then slumped by 87.07% to $1.0 million in 2025, then retreated by 4.16% to $991000.0 in 2026.
• The last three Operating Leases figures came in at $991000.0 (Q1 2026), $1.0 million (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.